Clinical trials: Newly Diagnosed Multiple Myeloma (NDMM)
Newly Diagnosed Multiple Myeloma (NDMM)
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple…
- Trial name
- NCT07891923
- Testing
- Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone)
- Where
- 2 sites in India
- Volunteers
- 52 people
- Sponsor
- Tata Memorial Centre
Newly Diagnosed Multiple Myeloma (NDMM)
REAL World IMROZ OutcomEs (REALIZE Study)
Demonstrating the real-world effectiveness of Isa-VRD in routine NHS care is the key aim for this proposal Isatuximab (Isa) is an IgG1 monoclonal antibody that binds a specific epitope on the human CD38 receptor and has…
- Trial name
- REALIZE (NCT07889323)
- Volunteers
- 150 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Newly Diagnosed Multiple Myeloma (NDMM)
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete…
- Trial name
- DURGA-6 (NCT07735637)
- Testing
- AZD0120, Cyclophosphamide, Fludarabine
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
18F-Fluciclovine PET/CT in Multiple Myeloma
Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT06103838
- Testing
- 18F-fluciclovine injection, 18F-FDG PET/CT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for…
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
- Trial name
- ELDORADO (NCT07247097)
- Testing
- Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Massachusetts General Hospital
Multiple Myloma, Newly Diagnosed Multiple Myeloma (NDMM)
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed multiple myeloma.
- Trial name
- NCT07652138
- Testing
- BCMA/CD19-targeted allogeneic CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Trial name
- NCT04653246
- Testing
- Isatuximab, Lenalidomide, Bortezomib Injection
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jacob Laubach, MD
Newly Diagnosed Multiple Myeloma (NDMM)
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China.
- Trial name
- PRIMARY (NCT07296627)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking University People's Hospital
Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT, Newly Diagnosed Multiple Myeloma (NDMM)
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed cytogenetically high-risk multiple myeloma…
- Trial name
- NCT07114432
- Testing
- BCMA/CD19-targeted allogeneic CAR-T
- Where
- 2 sites in China
- Volunteers
- 19 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Newly Diagnosed Multiple Myeloma (NDMM)
Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients
This study investigates newly diagnosed multiple myeloma patients following standard of care treatment. The primary endpoint of the study is to determine minimal residual disease (MRD) by combining 2 techniques in order to better…
- Trial name
- IMMPROVED (NCT07087964)
- Where
- 4 sites in Belgium
- Volunteers
- 120 people
- Sponsor
- Universiteit Antwerpen